SOD模拟及其抗氧化和抗炎症功能的研究进展*

超氧化物歧化酶(superoxide dismutase, 简称SOD) 作为生物体内超氧离子自由基的清除剂, 具备有效抗氧化、抗炎症、抗衰老之功效, 并用于临床, 其化学模拟引起了人们的广泛研究兴趣。本文将简要介绍近年来SOD 人工模拟酶及其生物医学活性研究所取得的重要进展, 特别是Cu,Zn-SOD 模拟物结构与功能的相互关系、Mn-SOD 模拟物的生物活性及其医学应用。     

锰（Ⅱ）配合物的合成及对超氧化物歧化酶的模拟

我们曾合成了一系列铜的大环配合物,在生物体系中有强的SOD活性。为寻求稳定性高且活性也高的Mn-SOD模拟物,我们用Ba~(2+)及Pb~(2+)为模板剂合成了2个新的锰大环和1个锰开环配合物(图1),探讨了其活性和结构的关系,同时还合成了一些锰的羧酸盐配合物与之比较。结果表明,大环配合物的活性比前人作为Mn-SOD模拟物的羧酸盐配合物的高,这为获得Mn-SOD模拟物提供了有益的启示。     

小分子细胞自噬诱导剂用于治疗神经退行性疾病

大量突变和错误折叠的蛋白质在细胞内聚集是神经退行性疾病产生的基础，研究发现一些小分子可以通过引起细胞自噬而降解细胞内聚集的突变蛋白，为治疗神经退行性疾病提供了新的方法，本文对神经退行性疾病的发病机理，细胞自噬的机理以及对神经退行性疾病的作用进行了综述。     

肠道菌群及其代谢产物与神经退行性疾病关系研究进展

神经退行性疾病是一种发生于中枢神经系统,具有高度致残、致死性的疾病,主要发病人群为中老年群体,目前该类疾病的发病机制尚不清楚,没有有效的治疗策略。随着我国老龄化程度的加深,神经退行性疾病对居民身体健康造成严重威胁。肠道菌群作为寄生在胃肠道中的微生物,与人体呈互利共生的关系,对生命健康起到至关重要的作用,神经退行性疾病的发展伴随着肠道菌群及其相关代谢产物的改变。文章综述了肠道菌群及其代谢产物与神经退行性疾病相互影响的机制,并探讨通过肠道菌群治疗神经退行性疾病的潜在价值,以期为神经退行性疾病的治疗提供新的研究方向。     

槲皮万寿菊素金属配合物的合成、抗氧化活性及与DNA结合的研究

合成了槲皮万寿菊素铜(Ⅱ)、锌(Ⅱ)铁(Ⅲ)三种配合物,采用红外、紫外光谱及元素分析等方法分析了其配位情况,研究了配合物清除DPPH自由基、超氧阴离子自由基和羟基自由基的活性,并运用紫外光谱滴定实验,研究了配体及配合物与ct-DNA的相互作用.结果表明,配合物较配体具有更强的清除DPPH自由基、超氧阴离子自由基和羟基自...     

人参活性成分在防治神经退行性疾病中应用的研究进展

神经退行性疾病是一类由神经系统内特定神经细胞的进程性病变或丢失而导致的神经功能障碍疾病，随着全球人口的老龄化，其发病率呈明显上升趋势。目前，此类疾病的发病机制尚不明确，临床上缺乏有效的治疗措施。人参含有多种活性成分，具有十分广泛的药理功效，在治疗神经退行性疾病中表现出巨大应用潜力。本文总结归纳了人参在神经退行性疾病防治中的活性成分及检测方法；然后，概述了人参在防治神经退行性疾病中的具体药理作用；最后，对其相关机制和通路进行了总结和评述。目前已经发现的具有神经退行性疾病的预防治疗活性的化学成分种类多，但其更多的活性成分及临床应用研究仍有待进一步深入研究。     

超氧化物歧化酶模型化合物的合成, 表征和活性测定

合成了二(2-苯并咪唑亚甲基)胺(N3)及其四种全新的过渡金属的双核配合物。通过元素分析、红外光谱和紫外光谱对配体及配合物进行了结构表征,利用邻苯三酚自氧化法测定了四种模拟化合物催化超氧阴离子自由基歧化反应的活性。     

基于质谱的蛋白质组学技术在神经退行性疾病生物标志物研究中的应用

蛋白质组学是在整体水平上研究细胞、组织或生物体蛋白质组成及变化规律的科学.与传统的生物学研究相比,蛋白质组学具有快速、灵敏、高通量的优点.神经退行性疾病是一类由神经系统内特定神经细胞的进程性病变或丢失而导致神经功能障碍的疾病,严重危害人类健康.近年来,基于质谱的蛋白质组学技术在神经退行性疾病的研究中得到了广泛应用.本文简要介绍了蛋白质组学在样品分离、多肽定量、质谱检测及生物标志物临床验证等方面的技术发展,并结合实例综述了基于质谱的蛋白质组学在神经退行性疾病生物标志物发现与验证中的研究进展.     

咪唑桥连双核铜SOD模拟物的电子结构及催化活性的理论研究

利用半经验PM3和密度泛函B3LYP方法研究了β环糊精咪唑桥连双核铜SOD模拟物({[Cu(L)·(H2O)(β-CD)]2(im)}3+)、模拟物的衍生物及模拟物与底物分子结合的复合物分子的电子结构, 运用自然键轨道(NBO)方法对该体系的电荷分布及成键特征进行了分析. 计算结果表明, 该模拟物中核心Cu离子与配体H2O分子的结合较弱, 在进行超氧阴离子自由基催化反应中可被其它配体所取代. 胍基的存在使得超氧化物歧化酶中Cu所带的正电荷增多, 而有利于催化反应的进行. 与其它配位原子相比, 与两个五元环连接的N原子与Cu配位能力相对下降, 这也将有利于提高Cu离子与底物的结合能力. 由于自由基分子形式, 使得超氧化物歧化酶模拟物与反应底物(O2·-)在酸性条件下结合后的络合物中五重态构型比相应的单重态构型更加稳定. 同时双核之间的咪唑桥环也对稳定该模拟物的构型起到了一定的作用.     

检测有机磷神经毒剂及模拟物的荧光探针

有机磷神经毒剂是一类具有极大杀伤力的化学毒剂,这类有机磷酸盐通过破坏人体内的神经递质乙酰胆碱酯酶麻痹人的中枢神经,很小的剂量就可致人死亡,因此对有机磷神经毒剂进行快速简便地检测具有重要意义。荧光化学传感具有灵敏度高、选择性好和响应时间短等优点,近些年来应用荧光传感方法对有机磷神经毒剂及其模拟物的检测越来越受到研究人员的关注。本篇综述对荧光传感的原理做了简要介绍,综述了近年来国内外研究者开发的各种用于有机磷神经毒剂及其模拟物检测的荧光新材料与新方法,并对荧光传感方法应用于有机磷神经毒剂检测的未来进行了展望。     

New Cyclodextrin‐Bearing 8‐Hydroxyquinoline Ligands as Multifunctional Molecules

Recent investigations have rekindled interest in 8‐hydroxyquinolines as therapeutic agents for cancer, Alzheimer’s disease, and other neurodegenerative disorders. Three new β‐cyclodextrin conjugates of 8‐hydroxyquinolines and their copper(II) and zinc(II) complexes have been synthesized and characterized spectroscopically. In addition to improving aqueous solubility, due to the presence of the cyclodextrin moiety, the hybrid systems have interesting characteristics including antioxidant activity, and their copper(II) complexes are efficient superoxide dismutase (SOD) mimics. The ligands and their copper(II) complexes show low cytotoxicity, attributed to the presence of the cyclodextrin moiety. These compounds have potential as therapeutic agents in diseases related both to metal dyshomeostasis and oxidative stress.     

Development of neurotrophic molecules for treatment of neurodegeneration

Over the past several years, neurotrophic factors have made considerable progress from the laboratory into the clinic. Evidence from preclinical and clinical studies indicates that it may be possible to use neurotrophic factors to prevent, slow the progression of, or even reverse the effects of a number of neurodegenerative diseases and other types of insults in both the central and peripheral nervous system. Their potential importance in the development of therapeutic agents against neurodegenerative disorders and nerve injury has led to a flurry of activity towards understanding their structure, function and signalling mechanisms. Approaches to develop pharmacological agents that target neurotrophic factors, their receptors or neurotrophic factors signalling pathways have been attempted. This review focuses on some of the major themes and lines of mechanistic and therapeutic advances in this fast-moving field of neuroscience.     

Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment

Decades have passed since the first nanoparticles-base medicine was approved for human cancer treatment, and the research and development of nanoparticles for drug delivery are always undergoing. Nowadays, the significant advances complicate nanoparticles’ branches, including liposomes, solid lipid nanoparticles, inorganic nanoparticles, micelles, nanovaccines and nano-antibodies, etc. These nanoparticles show numerous capabilities in treatment and diagnosis of stubborn diseases like cancer and neurodegenerative diseases, emerging as novel drug carriers or therapeutic agents in future. In this review, the complicated branches of nanoparticles are classified and summarized, with their property and functions concluded. Besides, there are also some delivery strategies that make nanoparticles smarter and more efficient in drug delivery, and frontiers in these strategies are also summarized in this review. Except these excellent works in newly-produced drug delivery nanoparticles, some points of view and future expectations are made in the end.     

'Magic bullets' for bone diseases: progress in rational design of bone-seeking medicinal agents

An ideal therapeutic agent for bone diseases should act solely on bone tissue with no pharmacological activity at other anatomical sites. Current therapeutic agents, however, do not usually display a preferential affinity to bones and non-specifically distribute throughout the body after administration. Attempts to design bone-specific agents have relied on engineering a desired therapeutic agent with bone-seeking molecules so that the latter delivers the therapeutic agents specifically to bones. In this critical review, we summarize the latest attempts to engineer bone-seeking therapeutic agents based on formulating therapeutic agents with bisphosphonates, a class of compounds with high affinity to biological apatite. We first provide a relevant summary of the structure of bone mineral and bisphosphonates, highlighting the mode of interaction between these two entities. The use of bisphosphonates in the diagnosis of bone diseases is then presented, since this application helps us to understand the bone-carrier properties of bisphosphonates under physiological conditions. A summary of recent attempts to formulate bisphosphonates with traditional therapeutic agents to restrict their activities to bone tissues is then provided, with special emphasis on the structure-function relationships of the engineered compounds. Finally, attempts to use bisphosphonates to deliver macromolecular therapeutics (i.e., proteins) are summarized, based on recent data from the authors' lab. The collective research into bone-seeking medicinal agents is progressively laying the foundation for next-generation 'magic bullets' that display desirable activities at the disease sites with no undesirable activity on other organ systems. (164 references.).     

Development of 99mTc-labelled complexes for imaging dopamine transporters in the brain

Technetium-99m (T_1/2=6h, 140keV) is the most commonly used short-lived radionuclide for diagnostic nuclear medicine imaging. It is important from an inorganic chemistry point of view to develop novel ligands and chelation chemistry associated with this radionuclide, because many patients could potentially benefit from advances in technetium chemistry. Recent studies showed that formation of tropane derivatives containing a neutral [Tc^VO]³⁺N₂S₂ complex are useful as dopamine transporter imaging agents. These agents may be important for the imaging of patients with Parkinson's and other neurodegenerative diseases.     

脂质纳米颗粒的制备及在基因治疗中的应用

基因治疗已经成为人类治疗疾病的一种重要手段.然而,为了将基因药物用于临床,需要更加复杂的递送系统.脂质纳米颗粒(LNPs)系统是目前领先的非病毒递送系统,在治疗诊断学方面取得了许多令人鼓舞的进展,其具有实现基因药物临床治疗应用的潜力.由于LNPs纳米尺寸的优势及类脂化合物的生物相容性和生物降解性,LNPs能够克服阻碍基...     

Current status,challenges and future directions in the treatment of neurodegenerative diseases by polymeric materials

Nowadays, one of the major challenges in biomedical and biopharmaceutical field is designing novel and effective anti-amyloidogenic inhibitors for the treatment of various human pathophysiologies associated with protein aggregation. In this milieu, numerous small molecules, polyphenols, surfactants, nanoparticles, etc. have been extensively studied to explore their anti-amyloidogenic properties, and thus provide huge scope for them to appear as future therapeutic agents in the treatment of amyloidogenic disorders. Recently, inspired by the fascinating properties of polymers such as non-toxicity, excellent biocompatibility, tuneable architectures, controllable degradation rate, possibility of multiple interaction between amyloidogenic protein/peptide and polymer, and excellent in vivo stability, polymer-based therapeutic agents have been extensively explored in the field of protein misfolding and aggregation. This mini-review article emphasizes the recent advancements of polymeric materials in the field of protein aggregation for ameliorating neurodegenerative diseases. Finally, we conclude this mini-review by providing some viewpoints on future directions.     

Development and application of nano-flavor-drug carriers in neurodegenerative diseases

Nano-drug carriers such as liposomes, polymer micelles, and polymer nanoparticles are used for neurodegenerative diseases, which can help drug pass the blood-brain barrier easily, and improve the therapeutic effect.     

Terpenoids as potential anti-Alzheimer's disease therapeutics

Alzheimer's disease (AD) is one of the most well-known neurodegenerative diseases and explains 50-60% of dementia in patients. The prevalence rate of AD is positively correlated with age and AD affects ≥ 40% of those over 85 years old. The major AD therapeutics available on the market are acetylcholinesterase inhibitors, such as tacrine and donepezil. New therapeutic agents that can block the disease-inducing mechanisms are essential. Diverse efforts have been made to discover anti-AD agents from natural sources. In this review article, we describe some representative terpenoids such as ginsenosides, gingkolides, and canabinoids as potential anti-AD agents. These compounds exhibit promising in vitro and in vivo biological activities, but are still waiting clinical trials. Additionally, we also discuss some terpenoids including cornel iridoid glycoside, oleanolic acid, tenuifolin, cryptotanshinone, and ursolic acid, which are under investigation for their in vitro and in vivo animal studies.